UK Pharmaceutical Supplier to India
India is the world's largest generic manufacturer, yet specific patient cases, rare diseases and specialist medicines still require sourcing from the UK. The Central Drugs Standard Control Organization (CDSCO) regulates medicine import and grants permission for named patient imports. Euro Biom is an MHRA-licensed UK pharmaceutical supplier for Indian tertiary hospitals, rare disease foundations and specialist clinics sourcing UK-licensed branded and orphan medicines, including products imported under the named patient route where they are not yet registered in India. We hold WDA wholesale dealer authorisation, source from a catalogue of 4,700+ UK-licensed products, and supply UK export documents to support the buyer's CDSCO application and customs clearance. Euro Biom trades exclusively in UK-licensed medicines.
Why Indian Hospitals and Rare Disease Foundations Struggle to Source UK Medicines
India manufactures most medicines it needs, but not all of them. When a treating physician at a major Indian hospital needs a UK-licensed specialty medicine, a rare disease orphan drug, or a locally unregistered brand, sourcing becomes unexpectedly hard.
Rule 36 Named Patient Permission Is Specific
Under Rule 36 of the Drugs and Cosmetics Rules 1945, an individual patient can apply to CDSCO (Form 12A) for permission to import a small quantity of medicine for personal use, and government hospitals have a separate import route under the New Drugs and Clinical Trials Rules 2019. The application requires a UK supplier with traceable GMP provenance and GDP documentation. Documentation requirements vary and should be confirmed with CDSCO.
Rare Disease Medicines Have No Indian Manufacturer
For some rare conditions, the treatment is a UK or European licensed medicine with no Indian manufacturer. Indian rare disease foundations and the National Policy for Rare Diseases rely on imports.
CDSCO Documentation Standards Are Non-Negotiable
Indian customs can reject consignments with incomplete or inconsistent paperwork. Certificate of Pharmaceutical Product, GMP, free sale certificate and GDP chain of custody must all be present and consistent. CDSCO and Indian customs check these documents closely.
Cold Chain Over a 9 Hour Direct Transit
Heathrow to Delhi or Mumbai is a 9 hour direct flight, often followed by customs delays of 24 to 72 hours. For temperature-sensitive UK-licensed medicines, temperature excursion risk over that full window is real. Tarmac exposure in 40 degree Mumbai summers is a known risk.
Urgent Oncology Requests Need Same-Day Response
When an Indian oncology patient's treatment pathway needs a UK-sourced medicine that is not available locally, the family and treating team need availability confirmation quickly, not an auto-acknowledgement. We respond the same working day.
Hospital Procurement Teams Need Single Accountability
Tertiary hospital pharmacy departments in India cannot manage five different wholesalers for one complex import. They need one UK counterparty who is responsible for the UK export and supplies the documents customs ask for.
An MHRA-Licensed UK Wholesaler Built for Indian Named Patient Supply
Importing a specialty medicine into India should be traceable and fast. Whether you are a consultant at a tertiary hospital sourcing a Rule 36 named patient medicine, a rare disease foundation coordinating a patient access programme, or a private clinic in Delhi managing a complex oncology case, we handle the UK side so your team can focus on the patient.
We hold MHRA Wholesale Dealer Authorisation WDA(H) 59239, source from a catalogue of 4,700+ UK-licensed medicines, and supply each shipment with UK export documentation to support the buyer's CDSCO application. Where available from the issuing authority or manufacturer, we supply supporting certificates and GDP records; buyers should confirm requirements with CDSCO.
Based near Heathrow, we arrange air freight to Delhi and Mumbai through specialist carriers, with 2-8°C medicines shipped from our contract storage site in temperature-controlled packaging with a data logger. For Rule 36 named patient cases, we respond the same day, with typical dispatch within 24 to 72 hours of order confirmation, subject to availability.
Discuss Your RequirementsWhat Indian Hospital Buyers Get from Euro Biom
The practical reasons tertiary hospitals, rare disease foundations and specialty clinics across India can use Euro Biom when they need UK-licensed medicines.
Publicly Verifiable MHRA Licence
WDA(H) 59239 on the UK MHRA public register. Your procurement team verifies us in under a minute. Credentials you can verify on the MHRA register when CDSCO asks to see supplier accreditation.
UK Export Documentation
Certificate of Pharmaceutical Product, Certificate of Free Sale, GMP certificates and GDP chain of custody, supplied where available to support the buyer's CDSCO application and customs clearance.
Support for Rule 36 Named Patient Applications
We can provide UK-side supply documentation for the buyer's Rule 36 application. Clean documentation and a traceable manufacturer chain, with typical dispatch within 24 to 72 hours of order confirmation, subject to availability.
UK-Licensed Medicines for Rare Conditions
Sourcing of UK-licensed orphan medicines for rare conditions, where within licence scope. We can supply UK-licensed product into an import route that the buyer or foundation holds.
UK-Licensed Sourcing Catalogue
4,700+ UK-licensed pharmaceutical products in our sourcing catalogue. When we confirm availability for an Indian named patient case, we have confirmed the line with a licensed UK source and give you an estimated timeline with each quote.
Cold Chain to Delhi and Mumbai
2-8°C UK-licensed medicines are shipped from our contract storage site in temperature-controlled packaging with a data logger, arranged with specialist carriers. Routing depends on the carrier.
Same-Day Response for Urgent Cases
When an Indian oncology or rare disease patient needs UK-sourced medicine urgently, we respond the same day with availability confirmation, with typical dispatch within 24 to 72 hours of order confirmation.
One Accountable Point of Contact
Direct contact with our team from enquiry through to dispatch, with shipment updates.
Pharmaceutical Supply Services for India
Four service lines built around the situations Indian tertiary hospitals, rare disease foundations and specialty clinics actually face when sourcing UK-licensed medicines.
Rule 36 Named Patient Supply
For Indian treating physicians sourcing UK-licensed medicines not yet registered in India, under Rule 36 of the Drugs and Cosmetics Rules 1945. We provide UK-side sourcing through the UK licensed supply chain, documentation to support the buyer's CDSCO application, and prompt dispatch once permission is confirmed by Central Drugs Standard Control Organization.
- Rule 36 application documentation support
- UK licensed supply chain sourcing with documented provenance
- Oncology and paediatric specialty products
- Same-day response for urgent cases
Rare Disease and Orphan Drug Supply
For Indian rare disease foundations, patient organisations and tertiary hospitals managing rare conditions. UK-licensed orphan medicine sourcing with GDP chain of custody and UK supply documents to support the buyer's CDSCO application.
- Sourcing of UK-licensed, non-biologic orphan medicines
- UK-side documentation for buyers using India's import routes
- Export documentation
Specialty Oncology Medicine Supply
For Indian oncology centres and tertiary hospitals sourcing UK-licensed oral targeted therapies and specialty oncology medicines not available through local channels. 2-8°C medicines ship in temperature-controlled packaging with a data logger, arranged with specialist carriers to Delhi, Mumbai and Chennai.
- Oral targeted therapy and specialty medicine supply
- 2-8°C shipping arranged with specialist carriers to Indian hub airports
- UK export documentation to support the buyer's CDSCO application
- Batch-level traceability documentation provided
Hospital Procurement and Shortage Response
For Indian hospital pharmacy teams managing urgent shortages or specific import requirements where the UK is the only reliable source. Same-day response on availability, clean documentation, export via London Heathrow under our WDA(H) authorisation.
- Same-day response on availability
- UK licensed supply chain sourcing
- Urgent shortage response
- Single accountable contact throughout
Built for Indian Hospital Buyers
Built for procurement teams and treating physicians at tertiary hospitals and rare disease foundations sourcing UK-licensed medicines for India.
Our Process for Indian Pharmaceutical Supply
From first enquiry to arrival at your hospital pharmacy, the process is built to be fast and traceable.
Step 1: Enquiry and Availability Confirmation
You send us the medicine name, strength, quantity and clinical context. We confirm UK-licensed availability the same day, quote price in GBP or USD, and outline the documentation we can provide for CDSCO or Rule 36 submission.
Step 2: Documentation Preparation
We prepare the export documentation pack from the CPP, GMP evidence, batch documentation and Free Sale Certificate available for each line, with GDP chain of custody, to support the buyer's CDSCO application.
Step 3: Dispatch and Cold Chain
Once payment and import permission are confirmed, we arrange air freight from Heathrow via direct Delhi or Mumbai air freight. 2-8°C products travel in temperature-controlled packaging with a data logger.
Step 4: Customs Clearance and Delivery
Your importer handles customs clearance; we answer UK-side documentation queries on request. Once cleared, onward delivery to your hospital pharmacy is coordinated with your chosen Indian logistics partner.
India Pharmaceutical Market Insight
The world's largest generic manufacturer still relies on imports for specific UK-licensed branded and specialty medicines.
India's pharmaceutical market, the world's third largest by volume and also large by value, is predominantly supplied by its massive domestic manufacturing sector. India supplies approximately 20 percent of global generic medicine demand and is one of the world's largest pharmaceutical manufacturing hubs. However, for specific UK-licensed branded medicines, orphan drugs, and specialty products not manufactured in India, the country's hospitals and importers source from international markets including the UK. The Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health regulates pharmaceutical imports.
India's pharmaceutical import framework operates under the Drugs and Cosmetics Act 1940 and Rules 1945. For registered medicines, CDSCO marketing authorisation is required. For unregistered medicines needed for individual patients, India operates two relevant pathways: the personal-use import permission under Rule 36 of the Drugs and Cosmetics Rules 1945 (for individuals) and the hospital import pathway through the Drug Controller General of India (DCGI). Additionally, the New Drugs and Clinical Trials Rules 2019 provide a route for government hospitals and medical institutions to apply to import certain unapproved drugs for patients with life-threatening conditions. Buyers should confirm the current requirements with CDSCO. These pathways are used by major Indian hospital networks to source UK-licensed medicines that are not available domestically.
India's private hospital sector, led by groups such as Apollo Hospitals, Fortis Healthcare, Max Healthcare, Manipal Hospitals, and Narayana Health, operates sophisticated pharmacy and import operations. These hospitals source UK-licensed branded medicines for patients who specifically require or request them, particularly in oncology, immunology, and rare diseases. India's medical tourism sector, which attracts international patients, also drives demand for UK and European-origin medicines that international patients expect.
Key therapeutic categories driving UK pharmaceutical imports to India include oncology (India's National Cancer Grid coordinates treatment across over 270 centres, with approximately 1.4 million new cancer cases annually), rare diseases (India's National Policy for Rare Diseases 2021 established treatment centres at eight Centres of Excellence), advanced specialty medicines not yet manufactured domestically, and dermatology and immunology products. The growing prevalence of non-communicable diseases, with diabetes affecting approximately 101 million Indians and hypertension approximately 315 million, is expanding demand for imported specialist medicines across all therapeutic areas.
Frequently Asked Questions About UK Medicine Supply to India
Practical questions from Indian hospital pharmacy teams, rare disease foundations and procurement managers, answered plainly.
Need a UK Pharmaceutical Supplier for India
Same-day response. MHRA-licensed. UK export documentation to support your CDSCO application. Air freight from Heathrow to Delhi, Mumbai, Chennai or Bangalore arranged with carriers. Tell us the medicine, the patient context and the timeline. We will tell you the same working day whether we can help.
MHRA WDA(H) 59239 · Company No. 15380737 · Registered England and Wales · work@eurobiom.co.uk
Get a tailored quote: Pharmaceutical Supply to India
Tell us what you need and our team responds the same working day. UK-licensed, MHRA WDA(H) 59239, verify on the MHRA register.